ClinicalTrials.gg
RecruitingNCT07695090LYRIC-HFUpdated Jul 17, 2026

Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients

A Phase 2 interventional study of Lumacaftor 200 MG and Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Qanatpharma AG. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Qanatpharma AG · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 224 studies in Cognitive Dysfunction with a site in Canada — 61 open to participants now, 80 under way, 7 of them phase 3. Cognitive Dysfunction · Canada.

Planned enrollment
87th of 171
60 · median 64
Started
2026
with 10 others
Phase 2
23 of 224
3 open now
Primary completion
2027-05
later than 46 of 79 live
Registered
202nd of 224
by date

Among the 224 studies in Cognitive Dysfunction with a site in Canada, this one is the 87th largest by planned enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2026, is one of 23 in phase 2, reaches primary completion later than 46 of the 79 other live ones, and was the 202nd registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

61 of the 224 studies in Cognitive Dysfunction with a site in Canada are open now. Recruiting first, the newest first:

55 more — sign in →

All 61 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Cognitive Dysfunction with a site in Canada, or all of them as a file.
02

Study summary

Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes. Currently, there are no specific treatments for CI aside from the current standard of care therapy for HF, making this a high unmet medical need. Impaired cerebral autoregulation is a proposed mechanistic factor that leads to cerebral hypoperfusion, ischemic damage and the development for CI. Preclinical data indicates that restoring CFTR-protein expression normalizes cerebral microvascular function and cerebral blood flow (CBF) in models of HF. The purpose of this study is to investigate whether CFTR-targeting therapy enhances cerebral perfusion and cognitive function in heart failure patients using the CFTR-corrector Lumacaftor.

Read the detailed description

Recent preclinical research has identified wild-type cystic fibrosis transmembrane conductance regulator (CFTR) in cerebral artery smooth muscle cells as a key protein involved in the myogenic mechanism governing cerebrovascular reactivity and a potential therapeutic target. In experimental models of HF, CFTR-protein expression is downregulated, which is associated with increased vascular tone, reduced cerebral blood flow, increased neuronal damage and poorer scores on functional tests. Treatment with CFTR-correctors reverses the pathology and normalizes cerebral artery CFTR-expression, vascular tone, CBF, neuronal health and functional outcome. Lumacaftor is an existing small-molecule CFTR-corrector that increases the abundance of CFTR-protein at the cell membrane by augmenting its trafficking and stability. It is currently approved as part of a combination therapy (lumacaftor/ivacaftor) in cystic fibrosis patients with the CFTR F508del gene mutation.

The purpose of this trial is to build on the CFTR-stabilizing properties of lumacaftor in HF patients and determine whether clinical application of a CFTR-stabilizing treatment improves cerebral perfusion and cognitive performance. The study is a Phase II proof-of-concept, randomized, parallel group, placebo-controlled, double-blind, longitudinal, single treatment center trial of 60 stable adults with HFrEF (no hospitalization within 3 months) on optimal goal-directed medical therapy treated with lumacaftor vs. identical placebo. This will include participants who are New York Heart Association (NYHA) class II-III, with reduced cardiac output and an EF of \<40%.

Following eligibility assessment and consent procedures, participants will undergo screening to measure baseline CBF using perfusion-weighted magnetic resonance imaging (MRI). Participants enrolled in the study will be allocated 1:1 to receive lumacaftor 200 mg q12 or identical placebo for 30 days. A follow-up cerebral MRI will assess the change from baseline at 1 month in global CBF as the primary outcome measure of the trial. In additional to safety metrics, a battery of neurocognitive assessments will be administered using the Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT), the Hospital Anxiety and Depression Scale (HADS) and the Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) to determine changes from baseline, at 1 month and 3 months in cognitive function, mental health, and quality of life as key secondary outcomes.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Keywords

  • Heart Failure with Reduced Ejection Fraction
  • Cognitive Impairment
  • Cerebral Blood Flow
  • CFTR
  • Microvascular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants screened for enrolment must meet all of the following criteria to be eligible for study participation:

  1. Provide written
  2. Aged 18 years or older with stable heart failure class II-III, with reduced cardiac output and an EF of \<40% on optimal goal directed medical therapy as per CCS Guidelines and the AHA/ACC/HFSA Guidelines for the Management of Heart Failure
  3. No hospital admissions for inpatient care in 3 months prior to study
  4. CBF at screening of ≤45 mL/100g/min
  5. Able to comply with study procedures
  6. Female participants must fulfill at least one of the following:

    1. Negative serum pregnancy (β-hCG) test at screening if participant is of (defined as having gone through menarche and not )
    2. Post-menopausal for a minimum of 1 year (defined as 12 consecutive months with no menses without an alternative medical cause) Be surgically sterile for a minimum of 6 months (achieved through partial/total hysterectomy, bilateral oophorectomy, or bilateral salpingectomy; note that tubal ligation is not considered a method of permanent sterilization)
  7. Agree to avoid pregnancy and be willing to use medically acceptable methods of for the duration of study and for 1 month after the last dose of the IMP (for females) and for 3 months after the last dose (for males)

Exclusion criteria

Exclusion criteria

Participants screened for enrolment, meeting any of the following criteria are not eligible for study participation:

  1. Participants with symptomatic HF who have non-MRI compatible cardiac implantable electronic devices (CIEDs), such as a cardiac defibrillator or pacemaker, or in whom this is required within 3 months of the study
  2. Those requiring coronary revascularisation in 6 months following the study
  3. Participants with cystic fibrosis (CF) or any other condition that may require use of CFTR modulating agents
  4. Participants using antiallergics (e.g., montelukast), antibiotics (e.g., clarithromycin), anticoagulants (e.g., warfarin), anticonvulsants (e.g., carbamazepine), antidepressants (e.g., citalopram), antifungals (e.g., fluconazole), anti-mycobacterials (e.g., rifabutin), barbituates, benzodiazepines (e.g., midazolam), (e.g., cyclosporine), proton pump inhibitors (e.g., esomeprazole) within 30 days of trial start
  5. A history of or known seropositivity for (HIV) and active and/or C infection
  6. Participants with moderate or severe hepatic disease (such as cirrhosis), or impaired liver function tests defined as serum and/or AST >3 x the (ULN) or total >2 x ULN
  7. Resting heart rate of >100 bpm
  8. Symptomatic blood pressure \<90 mmHg systolic
  9. Any major deviation in clinical lab values and/or deemed at baseline that in the opinion of the investigator would compromise the outcome of the trial as it relates to the active therapy
  10. Any clinically significant abnormalities in physical examination, neurological examination, vital signs, safety laboratory tests, and/or electrocardiograms that may impact the safety of the participant, in the opinion of the investigator
  11. Any suicidal behaviour in the past 2 years (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour), or any suicidal ideation (type 4 or 5) in the last 6 months (i.e., active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent), as defined by the C-SSRS
  12. Participants currently experiencing any clinically significant or unstable medical condition that in the opinion of the investigator might limit their ability to complete the study, or to comply with the requirements of the protocol, including dermatologic disease, haematological disease, pulmonary disease, kidney disease, hepatic disease, gastrointestinal disease, genitourinary disease, endocrine disease, neurological disease, and psychiatric disease
  13. Participants with severe (COPD), or demonstrating a significant degree of pulmonary obstruction with a (FEV1) or forced vital capacity (FVC) that is \<70% of the predicted normal value, or FEV/FVC ratio that is \<65%
  14. Females having used implanted, injected, intravaginal, or intrauterine hormonal within 6 months prior to first study drug administration.
  15. Females taking oral or transdermal hormonal contraceptives within 30 days prior to first study drug administration
  16. Female participants who are currently breastfeeding or planning to breastfeed
  17. Any not considered cured (except basal cell carcinoma of the skin). A participant is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening
  18. Unstable coronary syndromes
  19. Moderate or severe valvular disease
  20. >40 kg/m2
  21. Estimated (eGFR) of \<30 ml/m2
  22. Participants with a ferro-magnetic aneurysm clip or vascular clamp that is non-MRI compatible
  23. Claustrophobia or inability to undergo MRI without sedation
  24. Any other recognized CMRI as per local guidelines
  25. Participants that have participated in a clinical study during the 3 months prior to screening, or that plan to participate in another clinical study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Lumacaftor

    Participants receive 1 tablet of Lumacaftor 200 mg twice daily for 30 days.

    Drug: Lumacaftor 200 MG

  • Placebo comparator
    Placebo

    Participants receive 1 tablet of Lumacaftor placebo tablet twice daily for 30 days.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of lumacaftor treatment in increasing cerebral blood flow versus placebo in HFrEF patients.

    Change from baseline in global cerebral blood flow at 1 month using treatment or placebo as assessed by perfusion weighted MRI.

    Time frame: Baseline and 1 month

Secondary outcomes

  1. Rate of treatment-emergent adverse events as assessed by MedDRA.

    Number of treatment-emergent AEs by severity and treatment received. This will capture participants who received at least one dose of treatment.

    Time frame: Baseline up to Day 90

  2. Number of participants with clinically significant changes from baseline in physical examinations findings at 1 week, 1 month and 3 months.

    Time frame: Baseline, 1 week, 1 month and 3 months

  3. Number of participants with clinically significant changes from baseline in vital signs at 1 week, 1 month and 3 months.

    Time frame: Baseline, 1 week, 1 month and 3 months

  4. Number of participants with clinically significant changes from baseline in electrocardiograms (ECGs) at 1 week, 1 month and 3 months.

    Time frame: Baseline, 1 week, 1 month and 3 months

  5. Number of participants with clinically significant changes from baseline in laboratory test results at 1 week, 1 month and 3 months.

    Time frame: Baseline, 1 week, 1 month and 3 months

  6. Number of participants with clinically significant changes from baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) at 1 week, 1 month and 3 months.

    The C-SSRS is a questionnaire that captures severity and intensity of suicidal ideation and the number of suicidal behavioural attempts.

    Time frame: Baseline, 1 week, 1 month and 3 months

  7. Changes from baseline in Montreal Cognitive Assessment (MoCA) scores at 1 month and 3 months.

    MoCA is a screening tool for global cognitive function over several domains (memory, attention, language, visuospatial skills, and executive function). Scoring is 0-30-points, with higher scores indicating better global cognition function.

    Time frame: Baseline, 1 month and 3 months

  8. Changes from baseline in the 36-Item Short Form Health Survey (SF-36) scores at 1 month and 3 months.

    The SF-36 is a self-report, general measure of health status and quality of life, assessing eight domains (physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions). Scoring is 0-100 points for each domain, with higher scores indicating a more favourable health state.

    Time frame: Baseline, 1 month and 3 months

  9. Changes from baseline in the Hospital Anxiety and Depression Scale (HADS) scores at 1 month and 3 months.

    HADS is a self-report, 14-item measure to screen for depression and anxiety disorders among non-psychiatric, medically ill, outpatient populations. Scoring is 7 points for each domain of depression and anxiety, with scores of less than 7 for non-cases, 8-10 for mild cases, 11-14 for moderate cases and 15-21 for severe cases.

    Time frame: Baseline, 1 month and 3 months

  10. Changes from baseline in the Trail-Making-Test (TMT) scores at 1 month and 3 months.

    The TMT is an attention and task-switching, two-part test to measure executive and psychomotor function by connecting a series of dots accurately. Scoring is based on time to completion, with a score of more than 70-78 seconds deficient for TMT-A and a score of more than 180-273 seconds deficient for TMT-B.

    Time frame: Baseline, 1 month and 3 months

07

Study locations

1 of 2 sites recruiting
  • St. Michael's Hospital
    Toronto, Ontario M5B 1M8, Canada
    Recruiting
    • Research Coordinator · Contact
    • Kim Connelly, MD · Principal investigator
  • University Health Network (UHN) Peter Munk Cardiac Centre
    Toronto, Ontario M5G2N2, Canada
    Not yet recruiting
    • Research Coordinator · Contact
    • Filio Billia, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Qanatpharma will provide access upon request to individual de-identified participant data reported in the publication beginning 12 months after publication and for up to 36 months following article publication. Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement. Contact information will be provided at the time of article publication.

Supporting information: Study protocol

Time frame: 12 months after article publication and for up to 36 months following article publication.

Access criteria: Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for May 2027, 10 months later.

Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 10 months is below that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
Jul 10, 2026
StartEst.
Jul 2026
Primary completionEst.
May 2027
CompletionEst.
Sep 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07695090
Lead sponsor
Qanatpharma AG
Collaborators
Qanatpharma Canada LTD
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

Qanatpharma Clinical Program Manager
Contact
info@qanatpharma.com
1-877-308-4220
Kim Connelly
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumacaftor

Start the discussion